⁶⁸Ga-FAPI-46
Phase 1Small molecule
⁶⁸Ga-FAPI-46 is one of 76 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Reminyl
WWim Janssens
Preclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sirturo
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ⁶⁸Ga-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EErasmus Medical Center